Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The use of additional treatment methods in inflammatory joints disease therapy is very important. But the main principles of diet therapy for patients with rheumatoid joint inflammation and reactive arthritis and possibility of focused impact on disease activity by means of alimentary factors have not still been formed out. The aim of the investigation was to study the effect of diet therapy including ω-3 polyunsaturated fatty acids (PUFAs) on joint syndrome evidence and on bone turnover markers of children with inflammatory joint diseases.
View Article and Find Full Text PDF[Effects of rumalon and arteparon correcting metabolism in the connective tissue on the functional state of the liver in toxic hepatitis].
Eksp Klin Farmakol
December 2000
Clinical Pharmacy Department, Ukrainian Pharmaceutical Academy, Kharkov, Ukraine.
Effects of the connective tissue metabolism correctors rumalon (a glycosaminoglycane peptide complex) and arteparon (glucosamine sulfate) on the cholepoietic and absorption-excretion functions of liver were studied on a model of toxic liver damage. Rumalon exhibits pronounced anticholelithiasis and cholagogic properties and improves the absorption-excretion liver function. Arteparon produced no cholagogic action, inhibited the elimination of bromosulfalein, and showed no anticholelithiasis activity.
View Article and Find Full Text PDFEffect of Rumalon (glycosaminoglycan-peptide) on the articular tissue.
Agents Actions Suppl
April 1993
Institute of Rheumatology, Praha, Czechoslovakia.
The effect of glycosaminoglycan-peptide complex (GPC) (Rumalon, made by Robapharm, Switzerland) on cells of the inflammatory periarticular infiltrate and on the articular chondrocytes was studied in experimentally induced papain arthropathy by means of image cytometry and biochemistry. The GPC therapy exhibited some antiinflammatory effect as documented by the reduction of DNA proliferative activity in the inflammatory infiltrate and lowered the activity of hydrolytic enzymes and enzyme inhibitors detected in chondrocytes.
View Article and Find Full Text PDFPharmacologic treatment of osteoarthritis.
Clin Ther
September 1992
Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick.
Current pharmacotherapy for osteoarthritis (OA) is aimed at relief of pain and functional disability. Although an inflammatory component may be found in some cases, there is little evidence that anti-inflammatory drugs commonly used in the treatment of OA provide more relief than simple analgesics. A growing body of knowledge about the pathophysiology of OA now offers opportunities to develop interventions aimed at retarding the progressive degeneration of articular cartilage.
View Article and Find Full Text PDF[New approaches to developing drugs with cartilage protective properties].
Vestn Ross Akad Med Nauk
May 1993
The conjuncture and technological analysis was made of the current status and approaches to further development of the drugs--chondroprotectors on the basis of glycosaminoglycans. The concept of the goal-oriented search of the new type of drugs for the treatment of diseases of joints and other pathologies was worded on the basis of the systematization and summarization of the reported data and the results of own investigations. This concept rests on the current views of biochemistry of the nature of metabolism and the mechanisms of its regulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!